Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands.
Radiother Oncol. 2021 Apr;157:210-218. doi: 10.1016/j.radonc.2021.01.014. Epub 2021 Feb 3.
Compared to volumetric modulated arc therapy (VMAT), clinical benefits are anticipated when treating thoracic tumours with intensity-modulated proton therapy (IMPT). However, the current concern of plan robustness as a result of motion hampers its wide clinical implementation. To define an optimal protocol to treat lung and oesophageal cancers, we present a comprehensive evaluation of IMPT planning strategies, based on patient 4DCTs and machine log files.
For ten lung and ten oesophageal cancer patients, a planning 4DCT and weekly repeated 4DCTs were collected. For these twenty patients, the CTV volume and motion were assessed based on the 4DCTs. In addition to clinical VMAT plans, layered rescanned 3D and 4D robust optimised IMPT plans (IMPT_3D and IMPT_4D respectively) were generated, and approved clinically, for all patients. The IMPT plans were then delivered in dry runs at our proton facility to obtain log files, and subsequently evaluated through our 4D robustness evaluation method (4DREM). With this method, for each evaluated plan, fourteen 4D accumulated scenario doses were obtained, representing 14 possible fractionated treatment courses.
From VMAT to IMPT_3D, nominal D(lungs-GTV) decreased 2.75 ± 0.56 Gy and 3.76 ± 0.92 Gy over all lung and oesophageal cancer patients, respectively. A more pronounced reduction was verified for D(heart): 5.38 ± 7.36 Gy (lung cases) and 9.51 ± 2.25 Gy (oesophagus cases). Target coverage robustness of IMPT_3D was sufficient for 18/20 patients. Averaged dose in critical structures over all 4DREM scenarios changed only slightly for both IMPT_3D and IMPT_4D. Relative to IMPT_3D, no gain in IMPT_4D was observed.
The dosimetric superiority of IMPT over VMAT has been established. For most thoracic tumours, our IMPT_3D planning protocol showed to be robust and clinically suitable. Nevertheless, accurate patient positioning and adapting to anatomical variations over the course of treatment remain compulsory.
与容积调强弧形治疗(VMAT)相比,调强质子治疗(IMPT)治疗胸肿瘤预计具有临床优势。然而,目前由于运动导致计划稳健性的担忧阻碍了其广泛的临床应用。为了定义治疗肺癌和食道癌的最佳方案,我们根据患者的 4DCT 和机器日志文件,对 IMPT 计划策略进行了全面评估。
对 10 例肺癌和 10 例食道癌患者进行了规划 4DCT 和每周重复 4DCT 采集。基于 4DCT 对这 20 例患者的 CTV 体积和运动进行了评估。除了临床 VMAT 计划外,还为所有患者生成了分层重扫 3D 和 4D 稳健优化的 IMPT 计划(分别为 IMPT_3D 和 IMPT_4D),并获得了临床批准。然后在我们的质子设施进行干运行以获取日志文件,并随后通过我们的 4D 稳健性评估方法(4DREM)进行评估。通过这种方法,对于每个评估的计划,获得了 14 个 4D 累积情景剂量,代表 14 个可能的分次治疗过程。
从 VMAT 到 IMPT_3D,所有肺癌和食道癌患者的肺部 GTV 剂量 D(lungs-GTV)分别降低了 2.75±0.56 Gy 和 3.76±0.92 Gy。对于心脏剂量 D(heart),降低更为明显:5.38±7.36 Gy(肺癌病例)和 9.51±2.25 Gy(食道癌病例)。20 例患者中有 18 例 IMPT_3D 的靶区覆盖稳健性足够。在所有 4DREM 场景中,关键结构的平均剂量对于 IMPT_3D 和 IMPT_4D 仅略有变化。与 IMPT_3D 相比,IMPT_4D 没有优势。
已经证实 IMPT 比 VMAT 的剂量优势。对于大多数胸肿瘤,我们的 IMPT_3D 计划方案显示出稳健性和临床适用性。然而,仍然需要对患者进行准确的定位,并在治疗过程中适应解剖学变化。